Company: GCTS
Filing Date: 2025-03-26
Form Type: 424B3
Source: 0000929638-25-001281
Chunk: 157

Company: GCT Semiconductor Holding, Inc.
Filing Date: 2025-03-26
Form: 424B3
Chunk 157
---
 In accordance with our Charter, our Board is divided into three classes with only one class of directors being elected at each annual meeting of our stockholders and each director is serving a three-year term. The following table sets forth in detail.

| Director         |     | Class     |     | Expiration of Term of Director |
| Dr. Kukjin Chun  |     | Class I   |     |                           2025 |
| Nelson C. Chan   |     | Class I   |     |                           2025 |
| Robert Barker    |     | Class II  |     |                           2026 |
| Hyunsoo Shin     |     | Class II  |     |                           2026 |
| John Schlaefer   |     | Class III |     |                           2027 |
| Jeff Tuder       |     | Class III |     |                           2027 |
| Dr. Kyeongho Lee |     | Class III |     |                           2027 |

Family Relationships None of our directors or executive officers has a family relationship as defined in Item 401 of Regulation S-K. 81 Independence of the Board As required under NYSE listing standards, a majority of the members of a listed company’s Board must qualify as “independent,” as affirmatively determined by the Board. The Board consults with the Company’s counsel to ensure that the Board’s determinations are consistent with relevant securities and other laws and regulations regarding the definition of “independence,” including those set forth in pertinent listing standards of Nasdaq, as in effect from time to time. Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and the Company, its senior management and its independent auditors, the Board has affirmatively determined that the following directors, representing a majority of the members of the Board, are independent directors within the meaning of the applicable NYSE listing standards: Dr. Kyeongho Lee, Robert Barker, Dr. Kukjin Chun, Hyunsoo Shin, Jeff Tuder, and Nelson C. Chan. In making this determination, the Board found that none of these directors had a material or other disqualifying relationship with the Company. In the determination of Dr. Lee’s independence, the Board considered his relationship with a major stockholder of the Company and certain loan transactions between Dr. Lee and one of our subsidiaries. As Mr. Schlaefer serves as our Chief Executive Officer, he